Ivabradin Abz

Ivabradine, the active ingredient in Ivabradin Abz, is a If channel inhibitor presented as an oral formulation for oral use. It reduces heart rate and is indicated for chronic stable angina pectoris and heart failure with reduced ejection fraction in adult patients.

GNH USA supplies Ivabradin Abz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradin Abz acts on the cardiac If current to manage conditions where heart‑rate reduction is therapeutic. - Chronic stable angina pectoris: decreases the frequency of angina attacks by lowering heart rate without affecting contractility. - Heart failure with reduced ejection fraction: improves exercise capacity and reduces hospitalization risk by maintaining a lower resting heart rate.

Adverse reactions may occur with ivabradine therapy.

Common Side Effects: - Visual disturbances (phosphenes): transient luminous phenomena. - Bradycardia: resting heart rate below 50 bpm. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Fatigue or general weakness. - Blurred vision.

Serious or Rare Side Effects: - Symptomatic severe bradycardia requiring medical intervention. - Atrial fibrillation or other clinically significant arrhythmias. - Persistent visual impairment or retinal abnormalities. - Hypotension with syncope. - Allergic reactions such as rash or angioedema.

Before initiating therapy, several safety considerations are recommended. - Monitor heart rate: ensure resting HR > 50 bpm prior to start and during dose adjustments. - Avoid in severe hepatic impairment: reduced clearance may increase exposure. - Caution with concomitant beta‑blockers: risk of excessive bradycardia. - Use carefully in patients with sick sinus syndrome or atrioventricular block. - Store at room temperature: keep in the original pack, protect from moisture and light.

Ivabradine may interact with other medicines that affect its metabolism or heart‑rate control.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): can markedly increase ivabradine plasma levels. - Co‑administration with other heart‑rate‑lowering agents (e.g., digoxin, verapamil): risk of severe bradycardia.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin): monitor heart rate and adjust dose if needed. - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce therapeutic effect. - Concurrent antihypertensives: observe blood pressure for additive hypotensive effect.